The permanent J-code for ITVISMA^® is J3405, and goes into effect starting on July 1, 2026 for all sites of care.

Consider appropriate patient types. Scarlette hasn’t received ITVISMA. Individuals shown were compensated for their time. Scarlette R., 17 years old. Student. Living with SMA.

Sandra

History:
Age: 10 years old¹
Treatment history: supportive care only; no prior SMN-targeted therapy¹
Age at symptom onset: 18 months old²

Milestones¹:
Sit without support: YES
Stand with assistance: YES
Walk without assistance: NO

Current status:
It was considered a triumph when Sandra began grade school, but she’s experiencing increasing difficulty moving between rooms at her school. She often stays behind and does not participate in activities.

Considerations:
Sandra’s parents recognize she’s reaching the age when motor symptoms tend to worsen without spinal muscular atrophy (SMA) treatment. Financial constraints, insurance barriers, and living in a rural area with limited access to neurology specialists have meant Sandra has only received supportive care to date. As Sandra’s mobility challenges increase, her parents are seeking a therapy that has potential to improve motor function as she grows so as not to disrupt her schooling. Minimizing dosing requirements as part of her long-term SMA management plan may also support their goals as they proactively plan for her future.

This hypothetical patient profile is based on patient experiences seen in clinical practice. This patient profile should not be used as a substitute for independent medical judgment. Models are for illustrative purposes and not actual patients. Individual results may vary.